GlassScriptPhysician profile
Peter Sami Salib
NPI 1639480569
$2,955.61
in general payments reported to CMS, 2019-2025
31 companies · $60.50 in 2025
The $60.50 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $591 · 2021: $814 · 2022: $706 · 2023: $123 · 2024: $133 · 2025: $60.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.28 | 2019-2022 | |
| Avion Pharmaceuticals | $316.90 | 2019-2021 | |
| Daiichi Sankyo INC. | $212.93 | 2019-2022 | |
| Novo Nordisk INC | $200.02 | 2019-2022 | |
| Pfizer INC. | $176.03 | 2019-2024 | |
| Hologic Sales and Service, LLC | $144.29 | 2020-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
| Mylan Pharmaceuticals INC. | $140.81 | 2019-2022 | |
| Myriad Women'S Health, INC. | $122.73 | 2023 | Myrisk |
| Therapeuticsmd, INC. | $108.04 | 2019-2021 | |
| Exeltis, USA INC. | $107.35 | 2020-2022 | |
| Organon LLC | $74.14 | 2021-2024 | |
| Coopersurgical, INC. | $73.01 | 2019-2025 | Endosee, Paragard T 380a |
| Biohaven Pharmaceuticals, INC. | $67.00 | 2021 | |
| Roche Diagnostics Corporation | $57.87 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.21 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $52.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $52.03 | 2019-2020 | |
| Agile Therapeutics, INC. | $47.87 | 2022 | |
| Mayne Pharma Commercial LLC | $42.45 | 2021-2022 | |
| Evofem Biosciences, INC. | $41.65 | 2021 | |
| Ethicon US, LLC | $36.88 | 2020-2024 | Evarrest, Surgicel Nu-Knit, Ethicon |
| Biohaven Pharmaceutical Holding Company LTD. | $33.80 | 2022 | |
| Amag Pharmaceuticals, INC. | $26.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.51 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $17.38 | 2019 | |
| Sage Therapeutics, LLC | $16.33 | 2021 | |
| Smith+Nephew, INC. | $15.96 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.88 | 2020 | |
| Eisai INC. | $12.50 | 2019 | |
| Allergan, INC. | $12.48 | 2020 | |
| Astellas Pharma US INC | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Salib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.